
## Biotinylated Human HLA-A\*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Prote

## Cat. No. MHC-HM455B


Description	
Source	Recombinant Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein is expressed from E.coli with with His tag and Avi tag at the C-Terminus.
	It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGADGVGK peptide.
Accession	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVGADGVGK
Molecular Weight	The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE
Formulation and S	Storage
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before Iyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt20 to -80°C for 3-6 months in unopened state after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background	
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Assay Data	

## Tris-Bis PAGE



Biotinylated HLA-A\*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.





The purity of Biotinylated HLA-A\*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer is greater than 95% as determined by SEC-HPLC.